Skip to Main Content

Despite the outcomes of both the presidential election and the Brexit vote, this could be a banner year for biopharma mergers and acquisitions, according to two new reports.

Biopharma valuations leveled off substantially in 2016, which sets the stage this year for several new divestitures and megadeals, according to a new report from consulting firm EY.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED